Computational Neurogenomics: A Revolution in Personalized Treatments for Brain Disorders

In a landmark interview with Genomic Press, published today in Genomic Psychiatry, Dr. Miguel E. Rentería, an influential Australian neuroscientist, shares his journey from Mexico and his vision for the future of personalized medicine. Dr. Rentería’s innovative work, which combines genomics, neuroscience, and cutting-edge data science, is set to revolutionize the way we understand and treat complex brain disorders like Parkinson’s disease and psychiatric conditions.

A Journey of Curiosity and Strategic Leadership

Dr. Rentería’s passion for science began in his childhood in Morelia, Mexico, where his inquisitive nature was recognized by a primary school teacher who foresaw his future as a scientist. This curiosity led him to become part of the inaugural cohort of the UNAM’s Genomic Sciences program in 2003, the same year the human genome draft was published.

His academic path then took him to Brisbane, Australia, where he pursued his PhD under Professors Nick Martin, Sarah Medland, and Margie Wright. During this time, he became a key contributor to the ENIGMA consortium, co-authoring a significant 2015 paper in Nature. A subsequent detour into science policy, supported by a Chevening Scholarship for a Master of Public Policy at Oxford, profoundly shaped his approach to research. Although a plan to establish a science-for-policy office in Mexico was ultimately halted, the experience taught him to be more strategic and intentional in his work. “That entire experience has had a lasting influence on my work as a research leader today,” he noted in the interview.

Pioneering Parkinson’s Research in Australia and Beyond

Following his postdoctoral training at Brigham and Women’s Hospital and Harvard Medical School, Dr. Rentería shifted his focus to the genetics of Parkinson’s disease. This led to his most notable achievement: founding the Australian Parkinson’s Genetics Study (APGS). With nearly 20,000 volunteers, the APGS is now Australia’s largest Parkinson’s research cohort, established with crucial support from the Shake It Up Australia Foundation and The Michael J. Fox Foundation for Parkinson’s Research.

Dr. Rentería is now pushing the boundaries of this research by integrating wearable sensors and digital biomarkers. This “powerful new phenotyping layer” provides continuous, objective, real-world data on symptoms, which is vital for addressing the clinical heterogeneity of Parkinson’s disease. This approach aims to unravel why the disease manifests and progresses so differently among patients, a major challenge in the field.

Global Impact and a Commitment to Equity

Dr. Rentería’s influence extends globally through his leadership roles in international consortia. He serves as Co-Chair of ENIGMA’s working group on Suicidal Thoughts and Behaviours and is a founding member of the Psychiatric Genomics Consortium’s Suicide Genetics group. His impressive publication record includes over 120 papers, amassing more than 10,000 citations.

A core tenet of his work is a commitment to ensuring genetic research benefits all populations. He highlights a systemic issue where current knowledge is “disproportionately derived from studies of European ancestry populations,” leading to “evidence-biased medicine” for much of the world.

His contributions have been recognized with prestigious awards, including the 2024 Adèle Green Emerging Research Leadership Award, the Al & Val Rosenstrauss Fellowship, and an appointment as an Atlantic Fellow at the Global Brain Health Institute at UCSF.

Guided by the philosophy of “carpe diem,” Dr. Rentería is driven by a belief that his greatest achievements are yet to come. His vision is not only to advance the study of Parkinson’s but also to create methodologies that could be applied to other complex brain disorders, such as Alzheimer’s and depression, paving the way for a new era of truly personalized medicine.